Current Opinion in Hematology最新文献

筛选
英文 中文
Platelets come together, in sweet harmony?! 血小板聚集在一起,在甜蜜的和谐中?
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/MOH.0000000000000844
Dianne E van der Wal
{"title":"Platelets come together, in sweet harmony?!","authors":"Dianne E van der Wal","doi":"10.1097/MOH.0000000000000844","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000844","url":null,"abstract":"","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"32 1","pages":"1-3"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial introductions. 编辑介绍。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/MOH.0000000000000851
{"title":"Editorial introductions.","authors":"","doi":"10.1097/MOH.0000000000000851","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000851","url":null,"abstract":"","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"32 1","pages":"v"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCT in the widening spectrum of congenital immunodeficiencies. HCT 在不断扩大的先天性免疫缺陷中的应用。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI: 10.1097/MOH.0000000000000849
Rafaella Muratori, Carmem Bonfim
{"title":"HCT in the widening spectrum of congenital immunodeficiencies.","authors":"Rafaella Muratori, Carmem Bonfim","doi":"10.1097/MOH.0000000000000849","DOIUrl":"10.1097/MOH.0000000000000849","url":null,"abstract":"<p><strong>Purpose of review: </strong>Hematopoietic stem cell transplantation (HSCT) and inborn errors of immunity (IEI) have been closely linked since transplantation was first used to cure severe combined immunodeficiency (SCID) in 1968. Since then, novel genes and diseases have been continually added to the ongoing list of IEI, and new data on indications and outcomes have emerged. We review recent data and progress in the field of hematopoietic cell transplantation (HCT) for IEI including new diseases and complications.</p><p><strong>Recent findings: </strong>Emerging data from haploidentical transplants, newborn screening results, and multicentric studies reveals promising outcomes for IEI. Immune dysregulation diseases deserve special attention regarding disease control and may require additional drugs pretransplant. Female carriers of X-linked Chronic granulomatous may present with a severe phenotype warranting the need for HCT. Insights from infectious complications and long-term comorbidities should help guide decisions to treat IEI patients.</p><p><strong>Summary: </strong>From classical indications to recently described diseases, HCT for immunodeficiencies is a rapidly growing field. Novel data regarding alternative donor transplants, results from large cohorts, and long-term complications provide valuable knowledge for clinical practice.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"61-66"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet transfusion. 血小板输注。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-09-05 DOI: 10.1097/MOH.0000000000000843
Allison Mo, Erica Wood, Zoe McQuilten
{"title":"Platelet transfusion.","authors":"Allison Mo, Erica Wood, Zoe McQuilten","doi":"10.1097/MOH.0000000000000843","DOIUrl":"10.1097/MOH.0000000000000843","url":null,"abstract":"<p><strong>Purpose of review: </strong>Platelet transfusions, used as prophylaxis or treatment for bleeding, are potentially life-saving. In many countries, demand for platelet transfusion is rising. Platelets are a limited and costly resource, and it is vital that they are used appropriately. This study will explore the evidence behind platelet transfusions in different contexts, in particular recent and important research in this area.</p><p><strong>Recent findings: </strong>Recent randomized clinical trials demonstrate the efficacy of platelet transfusions in some contexts but potential detrimental effects in others. Platelet transfusions also carry risk of transfusion reactions, bacterial contamination and platelet transfusion refractoriness. Observational and clinical studies, which highlight approaches to mitigate these risks, will be discussed. There is growing interest in cold-stored or cryopreserved platelet units, which may improve platelet function and availability. Clinical trials also highlight the efficacy of other supportive measures such as tranexamic acid or thrombopoietin receptor agonists in patients with bleeding.</p><p><strong>Summary: </strong>Although platelet transfusions are beneficial in many patients, there remain many settings in which the optimal use of platelet transfusions is unclear, and some situations in which they may have detrimental effects. Future clinical trials are needed to determine optimal use of platelet transfusions in different patient populations.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"14-21"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery. 心血管疾病和治疗中的血小板源性细胞外囊泡--从维持体内平衡到靶向给药。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-08 DOI: 10.1097/MOH.0000000000000845
Luisa Weiss, Hayley Macleod, Patricia B Maguire
{"title":"Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery.","authors":"Luisa Weiss, Hayley Macleod, Patricia B Maguire","doi":"10.1097/MOH.0000000000000845","DOIUrl":"10.1097/MOH.0000000000000845","url":null,"abstract":"<p><strong>Purpose of review: </strong>Cardiovascular disease (CVD) remains a major global health burden. Rising incidences necessitate improved understanding of the pathophysiological processes underlying disease progression to foster the development of novel therapeutic strategies. Besides their well recognized role in CVD, platelet-derived extracellular vesicles (PEVs) mediate inter-organ cross talk and contribute to various inflammatory diseases.</p><p><strong>Recent findings: </strong>PEVs are readily accessible diagnostic biomarkers that mirror pathophysiological disease progression but also may confer cardioprotective properties. Monitoring the effects of modulation of PEV signatures through pharmacotherapies has also provided novel insights into treatment efficacy. Furthermore, exploiting their inherent ability to infiltrate thrombi, atherosclerotic plaques and solid tumours, PEVs as well as platelet-membrane coated nanoparticles are emerging as novel effective and targeted treatment options for CVD and cancer.</p><p><strong>Summary: </strong>Collectively, in-depth characterization of PEVs in various diseases ultimately enhances their use as diagnostic or prognostic biomarkers and potential therapeutic targets, making them clinically relevant candidates to positively impact patient outcomes.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"4-13"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Desialylation by neuraminidases in platelets, kiss of death or bittersweet? 血小板中神经氨酸酶的去酰化作用,死亡之吻还是苦乐参半?
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-08-30 DOI: 10.1097/MOH.0000000000000815
Nora Butta, Dianne E van der Wal
{"title":"Desialylation by neuraminidases in platelets, kiss of death or bittersweet?","authors":"Nora Butta, Dianne E van der Wal","doi":"10.1097/MOH.0000000000000815","DOIUrl":"10.1097/MOH.0000000000000815","url":null,"abstract":"<p><strong>Purpose of review: </strong>Loss of surface sialic acid by neuraminidases is known as 'desialylation'. Platelets are desialylated in bacterial or viral infections, during storage, senescence, various mutations, platelet auto antibodies, hemostasis and shear stress. In this review the recent literature on the different sialic acid capped glycan structures will be covered as well as platelet desialylation in inherited glycan disorders and induced by external neuraminidases.</p><p><strong>Recent findings: </strong>Neuraminidases are released from platelet intracellular stores and translocated to the platelet surface. Apart from clearance, loss of surface sialic acid by neuraminidases ('desialylation') affects platelet signaling including ligand binding and their procoagulant function. Platelets are also desialylated in infections, various mutations, presence of platelet auto antibodies.</p><p><strong>Summary: </strong>Since platelet desialylation occurs in various healthy and pathological conditions, measuring desialylation might be a new diagnostic tool.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"43-51"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PROTACs in platelets: emerging antithrombotic strategies and future perspectives. 血小板中的 PROTACs:新出现的抗血栓策略和未来展望。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-18 DOI: 10.1097/MOH.0000000000000846
Justin S Trory, Jordan Vautrinot, Carl J May, Ingeborg Hers
{"title":"PROTACs in platelets: emerging antithrombotic strategies and future perspectives.","authors":"Justin S Trory, Jordan Vautrinot, Carl J May, Ingeborg Hers","doi":"10.1097/MOH.0000000000000846","DOIUrl":"10.1097/MOH.0000000000000846","url":null,"abstract":"<p><strong>Purpose of review: </strong>Proteolysis-targeted chimeras (PROTACs) are heterobifunctional compounds that selectively target proteins for degradation and are an emerging therapeutic modality to treat diseases such as cancer and neurodegenerative disorders. This review will widen the area of application by highlighting the ability of PROTACs to remove proteins from the anucleate platelets and evaluate their antithrombotic potential.</p><p><strong>Recent findings: </strong>Proteomic and biochemical studies demonstrated that human platelets possess the Ubiquitin Proteasomal System as well as the E3 ligase cereblon (CRBN) and therefore may be susceptible to PROTAC-mediated protein degradation. Recent findings confirmed that CRBN ligand-based PROTACs targeting generic tyrosine kinases, Btk and/or Fak lead to efficacious and selective protein degradation in human platelets. Downregulation of Btk, a key player involved in signalling to thrombosis, but not haemostasis, resulted in impaired in-vitro thrombus formation.</p><p><strong>Summary: </strong>Platelets are susceptible to targeted protein degradation by CRBN ligand-based PROTACs and have limited ability to resynthesise proteins, ensuring long-term downregulation of target proteins. Therefore, PROTACs serve as an additional research tool to study platelet function and offer new therapeutic potential to prevent thrombosis. Future studies should focus on enhancing cell specificity to avoid on-target side effects on other blood cells.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"34-42"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel neutrophil biology insights underlying atypical chemokine receptor-1/Duffy antigen receptor of chemokines-associated neutropenia. 非典型趋化因子受体-1/达菲抗原受体与中性粒细胞减少症相关的中性粒细胞生物学新见解。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-07-24 DOI: 10.1097/MOH.0000000000000834
Johnson M Liu, Hongbo R Luo
{"title":"Novel neutrophil biology insights underlying atypical chemokine receptor-1/Duffy antigen receptor of chemokines-associated neutropenia.","authors":"Johnson M Liu, Hongbo R Luo","doi":"10.1097/MOH.0000000000000834","DOIUrl":"10.1097/MOH.0000000000000834","url":null,"abstract":"<p><strong>Purpose of review: </strong>Atypical chemokine receptor-1 (ACKR1)/Duffy antigen receptor of chemokines (DARC)-associated neutropenia (ADAN; OMIM 611862), previously named benign ethnic neutropenia, and present in two-thirds of individuals identifying as Black in the USA, is associated with mild to moderate decreases in peripheral neutrophil counts that nevertheless do not lead to increased infections. Consequently, recent initiatives have sought to establish normal neutrophil count reference ranges for ADAN, considering it a normal variant rather than a clinical disorder requiring medical intervention.</p><p><strong>Recent findings: </strong>A limited number of studies elucidating the mechanism of neutropenia in ADAN has suggested that neutrophils may redistribute from peripheral blood to the tissues including the spleen: this might explain why ADAN is not associated with increased risks of infection since the total number of neutrophils in the body remains normal. In this review, we critically examine the research underlying the molecular basis of ADAN.</p><p><strong>Summary: </strong>Insights into the biology of neutrophils and their trafficking may inform the clinical interpretation of neutropenia in ADAN. The bulk of research suggests that ADAN does not lead to a diminished host defense as do other forms of neutropenia. However, ADAN may lead to increased proinflammatory signaling, with possible implications for senescence of the immune system and predisposition to autoimmunity and cancer.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"302-306"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New insights of glycoprotein Ib-IX-V complex organization and glycoprotein Ibα in platelet biogenesis. 糖蛋白 Ib-IX-V 复合物组织和糖蛋白 Ibα 在血小板生物生成过程中的新见解。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-07-16 DOI: 10.1097/MOH.0000000000000832
Lulu Huang, Bojing Shao
{"title":"New insights of glycoprotein Ib-IX-V complex organization and glycoprotein Ibα in platelet biogenesis.","authors":"Lulu Huang, Bojing Shao","doi":"10.1097/MOH.0000000000000832","DOIUrl":"10.1097/MOH.0000000000000832","url":null,"abstract":"<p><strong>Purpose of review: </strong>Glycoprotein (GP) Ib-IX-V, a platelet surface receptor that plays a critical role in platelet adhesion and platelet-mediated immune responses, consists of GPIbα, GPIbβ, GPIX, and GPV in a stoichiometry of 2 : 4 : 2 : 1. Forming a complex is essential for GPIb-IX-V to function. GPIb-IX-V also plays an important role in platelet biogenesis by regulating the number and size of platelets. Yet how GPIb-IX-V regulates platelet biogenesis remains elusive. This review will summarize recent findings in the complex organization of GPIb-IX-V and its role in platelet biogenesis.</p><p><strong>Recent findings: </strong>Proteomics studies suggest that GPIbα, GPIbβ, GPIX, and GPV form the complex in a ratio of 1 : 2 : 1 : 1, which is supported by analysis of molecular weight of GPIb-IX-V and GPIb-IX and the structure of entire GPIb-IX-V. To activate platelets, GPIbα requires binding of CLEC-2 to trigger signals. Furthermore, disrupting the GPIbα anchorage to filamin A causes defects in platelet budding away from proplatelets leading to giant platelets and a low platelet count.</p><p><strong>Summary: </strong>New studies challenge the traditional model for the organization of GPIb-IX-V as a complex and indicate the role of GPIb-IX-V in platelet production. Those studies provide insights for GPIb-IX-V in the regulation of platelet activation and platelet biogenesis.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"294-301"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prophylactic red cell transfusions for sickle cell disease pregnancy: increased use of therapy could transform outcomes. 镰状细胞病妊娠的预防性红细胞输注:增加治疗的使用可改变预后。
IF 3.1 3区 医学
Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-08-22 DOI: 10.1097/MOH.0000000000000837
Sheinei Alan, Deva Sharma, Lydia H Pecker
{"title":"Prophylactic red cell transfusions for sickle cell disease pregnancy: increased use of therapy could transform outcomes.","authors":"Sheinei Alan, Deva Sharma, Lydia H Pecker","doi":"10.1097/MOH.0000000000000837","DOIUrl":"10.1097/MOH.0000000000000837","url":null,"abstract":"<p><strong>Purpose of review: </strong>Pregnancy for people with sickle cell disease (SCD) is high risk with persistently high rates of severe maternal and fetal mortality and morbidity. Transfusion therapy is the best-studied treatment for SCD in pregnancy; hydroxyurea is not usually used because of teratogenicity concerns. In high-resource settings, red cell transfusions are likely underutilized, while in low-resource settings, they may be altogether unavailable.</p><p><strong>Recent findings: </strong>A randomized controlled trial and meta-analysis, two of the strongest forms of clinical research, show transfusion significantly reduces maternal and fetal death, painful crisis, thrombosis, and acute respiratory failure. Downstream benefits of treatment are less well measured and may include improving maternal anemia, reducing opioid exposure, and avoiding hospitalization, which presents risk for additional complications. Alloimmunization is a particular transfusion risk in SCD. However, many strategies can mitigate this risk. Accordingly, the American Society of Hematology classifies chronic transfusion in pregnancy as low risk.</p><p><strong>Summary: </strong>Given the low risk classification, lack of alternative therapies, dismal, stagnant pregnancy outcomes and the potential for profound treatment benefit, wider use of chronic transfusion therapy for SCD pregnancy is likely indicated. This review discusses the benefits and potential risks of prophylactic transfusions for SCD pregnancy. Use of chronic transfusions during pregnancy is indicated to help urgently transform outcomes.</p>","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"285-293"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信